IVERIC bio (ISEE) Misses Q1 EPS by 4c

IVERIC bio (NASDAQ: ISEE) reported Q1 EPS of ($0.29), $0.04 worse than the analyst estimate of ($0.25).

“Iveric Bio is entering an important period as we remain focused on the execution of our ongoing Zimura GATHER2 clinical trial, which is our second Phase 3 clinical trial for Zimura for the treatment of geographic atrophy secondary to age-related macular degeneration. We are committed to completing recruitment for the GATHER2 trial in the third quarter of this year,” stated Glenn P. Sblendorio, Chief Executive Officer of Iveric Bio. “To date, both the recruitment and retention of patients in GATHER2 have exceeded our expectations. We are on track for initial, topline data from GATHER2 to be available approximately one year after the recruitment of the last patient in the GATHER2 clinical trial, plus the time needed for database closure and analysis of the initial, topline data.”

“A key goal of ours is to expand and advance our footprint in multiple stages and types of AMD,” stated Pravin U. Dugel, M.D., President of Iveric Bio. “We are excited by the opportunity to potentially expand the reach of Zimura beyond GA and to continue the development of IC-500, our HtrA1 inhibitor, which we expect could be complementary to Zimura in treating AMD patients. We remain committed to developing safe and effective therapeutic and gene therapy treatment options for retinal diseases with significant unmet medical needs.”

For earnings history and earnings-related data on IVERIC bio (ISEE) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Boost Run posts Q2 revenue of $31.1M, up 270% year over year
• Algorhythm Holdings (RIME) Tops Q2 EPS by 54c